Abstract 1754P
Background
Next Generation Sequencing / Comprehensive Genomic Profiling (NGS/CGP) have recently expanded, mainly in oncology. To guide healthcare decision-making, it is key to have a value framework (VF), which allows a transparent assessment of value criteria. In 2020, IECS published a VF for diagnostic tests in Latin America (Augustovski et al, VIH 2021 ). This study aims to enrich, update, and adapt the previous VF to develop an NGS/CGP VF targeted to oncology in Europe. The aim of this study is to identify value criteria/sub criteria from published VFs, map them to the current VF, and report an updated and evidence-based list of non-overlapping criteria for subsequent assessment of their relevance for an NGS/CGP VF in Europe.
Methods
A systematic review (SR) of VFs aimed at any type of health technology. A mapping was then performed to determine similarities and differences with the IECS VF criteria.
Results
A total of 43 VFs were identified from 2067 unduplicated records and grey literature. The vast majority (n=38, 88%) were developed in high-income countries, 30% (n=13) were oriented towards genetic testing and only 16% (n=7) targeted oncology. A total of 223 criteria (C) and sub criteria (SC) were retrieved (93% of them fully or partially included in IECS VF). The two most common criteria related to clinical benefit and economic aspects. VFs oriented to oncology had higher overlap with the IECS VF, as well as those VFs oriented to genetic testing. A total of 18 criteria (C) and 35 non-overlapping sub-criteria (SC) were listed (15C and 21SC from IECS VF and 3C and 14SC from the SR). Some examples of new potential criteria included quality assurance/improvement; and public health/population benefit.
Conclusions
Our study provides an evidence-based, user-oriented update of criteria and sub criteria for healthcare decision-making tailored for NGS/CGP genetic testing in oncology, which may be a helpful list of criteria for health technologies in general. This list will serve as the basis to adapt the existing VF with the assistance of key European experts and stakeholders in order to co-create a European NGS/CGP VF in oncology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute for Clinical Effectiveness and Health Policy (IECS).
Funding
Precision Cancer Consortium (PCC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23